当前位置: 首页 > 期刊 > 《中国医学创新》 > 2019年第23期
编号:13413960
LncRNA-MEG3作为急性髓系白血病预后标志物调控细胞增殖(1)
http://www.100md.com 2019年8月15日 《中国医学创新》 2019年第23期
     【摘要】 目的:探索长链非编码-MEG3(LncRNA-MEG3)与急性髓系白血病(AML)生存期的关系,并分析它对细胞增殖的调控作用。方法:采用过表达技术对AML细胞系HL-60、THP-1和U937的LncRNA-MEG3进行过表达,用MTT检测细胞增殖情况。收集初发未治的10例AML患者和10名健康人的骨髓标本及相关临床资料,用实时荧光定量PCR(qPCR)检测LncRNA-MEG3在骨髓中的表达情况。检测75例被确诊为AML患者骨髓中LncRNA-MEG3的表达情况,并跟踪随访5年,分析LncRNA-MEG3的表达与患者生存结局的关系。结果:与健康人比较,AML患者骨髓中LncRNA-MEG3的表达量明显下调,差异有统计学意义(P<0.01)。生存分析显示,MEG3低表达组患者的中位生存时间为21.162个月,明显短于MEG3高表达组的41.715个月(P<0.000 1)。MTT结果显示,LncRNA-MEG3过表达细胞组的细胞增殖明显低于阴性对照组,差异有统计学意义(P<0.05)。结论:LncRNA-MEG3在AML骨髓中表达下调,LncRNA-MEG3低表达可能是AML预后不良的新生物标记物,并能調控AML细胞的细胞增殖。

    【关键词】 急性髓系白血病; 长链非编码RNA; 细胞增殖; 生物标志物

    LncRNA-MEG3 as a Prognostic Marker of Acute Myeloid Leukemia Regulates Cell Proliferation/ZENG Jinlong,ZHOU Zhiheng,CHEN Baoxin,et al.//Medical Innovation of China,2019,16(23):00-005

    【Abstract】 Objective:To explore the relationship between long-chain non-coding-MEG3(LncRNA-MEG3)and the survival period of acute myeloid leukemia(AML),and to analyze its regulatory effect on cell proliferation.Method:LncRNA-MEG3 of AML cell lines HL-60,THP-1 and U937 were overexpressed by overexpression technique,and the proliferation of the cells was detected by MTT.Bone marrow samples and relevant clinical data of 10 untreated AML patients and 10 normal people were collected,and the expression of LncRNA-MEG3

    in bone marrow was detected by real-time quantitative PCR(qPCR).The expression of LncRNA-MEG3 in the bone marrow of 75 patients diagnosed with AML was detected and followed up for 5 years to analyze the relationship between the expression of LncRNA-MEG3 and survival outcome of patients.Result:Compared with healthy individuals,the expression of LncRNA-MEG3 in bone marrow of AML patients was significantly down-regulated,the difference was statistically significant(P<0.01).Survival analysis showed that the median survival time of patients in the MEG3 low-expression group was 21.162 months,significantly shorter than 41.715 months in the MEG3 high-expression group(P<0.000 1).MTT results showed that the proliferation of LncRNA-MEG3 overexpressed cells in the LncRNA-MEG3 overexpressed cells group was significantly lower than that in the negative control group,the difference was statistically significant(P<0.05).Conclusion:The expression of LncRNA-MEG3 in AML bone marrow is down-regulated,and the low expression of LncRNA-MEG3 may be a new biomarker of AML with poor prognosis,and can regulate the proliferation of AML cells.

    【Key words】 Acute myeloid leukemia; Long non coding RNA; Cell proliferation; Biomarker, http://www.100md.com(曾进龙 周志衡 陈宝欣 王彩霞)
1 2 3 4下一页